Tuesday, February 21, 2017 5:39:25 AM
New patents applicable to a broad range of markets, including pharmaceuticals and industrial products, among others
http://www.marketwired.com/press-release/applied-dna-sciences-expands-patent-portfolio-with-range-advancements-that-enable-companys-nasdaq-apdn-2197135.htm
STONY BROOK, NY--(Marketwired - February 21, 2017) - Applied DNA Sciences, Inc. ("Applied DNA") (NASDAQ: APDN) a provider of DNA-based supply-chain, anti-counterfeiting and anti-theft technology, product genotyping and product authentication solutions, is proud to announce a significant expansion of its U.S. and Global patent portfolio in 2016, demonstrating its ongoing commitment to innovation and leadership in the marketplace.
Applied DNA's U.S. and Global patent portfolio now totals 44 issued patents, with 84 applications pending. In 2016, Applied DNA was granted U.S. Patent Nos. 9,266,370, 9,290,819, 9,297,032, 9,412,284 and Canadian Patent No, 2,713,101. These newly issued patents provide broad long term protection for Applied DNA's core business verticals, including its fiberTyping, SigNature DNA, SigNature T and BackTrac platforms, as well as its bulk DNA production services.
U.S. Patent 9,290,819 is based upon Applied DNA's ground-breaking research in the genotyping of mature cotton fibers and provides strong protection of Applied DNA's fiberTyping services currently utilized by major U.S. retailers and brands as well as SigNature T supply chain partners. U.S. Patents 9,266,370 and 9,297,032 provide further protection for Applied DNA's SigNature DNA molecular taggant and the SigNature T platform, and their use in a broad range of markets, including, pharmaceuticals, consumer products, industrial materials, printing, and electronics. U.S. Patent 9,412,284 is the first in a new family of patents that protects the encoding and decoding of information within the 2-diminsional curves of a pattern, such as a military camouflage pattern. Canadian Patent No, 2,713,101 extends Applied DNA's protection of its unique bulk DNA production apparatus and methods to Canada.
Dr. James Hayward, president and CEO of Applied DNA, stated, "The continuous development of our intellectual property to advance the commercial adoption of our core technology platform, SigNature DNA, is central to our business model. These new patents and others under examination underpin our penetration of core business verticals with an uncopyable and unbreakable mark that can reduce risk and uncertainty across global supply chains. Our intellectual property estate is among our most valuable assets and we will look to further leverage this asset in the future."
Clay D. Shorrock, Esq., General Counsel for Applied DNA, stated: "Our commitment to innovation underpins our patent portfolio's strong growth in 2016. Our patents continue to validate our core technologies and confer a significant competitive advantage to the company. As we continue to innovate across our business lines, our patent portfolio is well positioned for substantial growth in 2017 and beyond."
Recent APDN News
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/04/2024 10:18:33 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/12/2024 09:25:36 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 02/12/2024 09:09:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/08/2024 09:05:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/08/2024 09:01:31 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/01/2024 09:05:28 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 01/26/2024 09:24:06 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/10/2024 10:16:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 12:00:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 09:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/07/2023 09:05:23 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 12/07/2023 09:01:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/06/2023 09:05:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2023 10:09:34 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/07/2023 10:02:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/20/2023 08:05:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/10/2023 08:05:45 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/10/2023 08:01:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2023 08:02:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/13/2023 09:04:44 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM